AIM ImmunoTech Announces Extension of Subscription Period of its Previously Announced Rights Offering to March 3, 2026

AIM ImmunoTech (NYSE American: AIM) extended the subscription period for its previously announced rights offering to 5:00 p.m. ET on March 3, 2026.

Rhea-AI Summary

AIM ImmunoTech (NYSE American: AIM) extended the subscription period for its previously announced rights offering to 5:00 p.m. ET on March 3, 2026. The offering commenced on February 11, 2026 and subscription rights are non-transferable and exercisable only during the subscription period.

The company stated the SEC declared its Form S-1 effective on February 10, 2026. Maxim Group LLC is engaged as dealer-manager and Broadridge will act as subscription agent for receipt of completed rights certificates and payment.

Positive

• Subscription period extended to March 3, 2026
• SEC declared Form S-1 effective on February 10, 2026
• Maxim Group engaged as dealer-manager

Negative

• Subscription rights are non-transferable and expire if unexercised
• Exercise of rights is irrevocable even if adverse information emerges
• Company may cancel or modify the rights offering prior to expiration

Argus Feb 25 session

-4.67% close to close Open Argus

Details

News Market Reaction – AIM

On Feb 25, the day this news came out, AIM closed 4.67% below the previous close.

Data tracked by StockTitan Argus for the Feb 25 session.

Key Figures

Rights offering size: $12.0 million Units offered: 12,000 Units Unit subscription price: $1,000 per Unit +5 more

Rights offering size

$12.0 million

Target gross proceeds if Units fully subscribed per recent offering filings

Units offered

12,000 Units

Maximum Units available in rights offering

Unit subscription price

$1,000 per Unit

Rights offering subscription price per Unit

Warrants per Unit

1,666 warrants

Five-year warrants included in each Unit at $1.20 exercise price

Conversion ratio

833 common shares

Common shares per Series G preferred share in each Unit

Exercise / conversion price

$1.20 per share

Exercise price for warrants and conversion price for Series G preferred

Shelf registration capacity

$100 million

Aggregate amount under S-3/A shelf filed 2025-06-27

New subscription deadline

5:00 p.m. ET, March 3, 2026

Extended expiration for non-transferable subscription rights

Previous Offering Reports

5 past events · Latest: Feb 12

Same Type 5 events

1. Feb 12

   Rights offering terms

   24h Move

   -6.4%

   Correction detailing rights offering size, unit structure and timelines.

2. Feb 11

   Rights offering launch

   24h Move

   -13.5%

   Commencement of rights offering with preferred shares and warrants package.

3. Jan 27

   Offering terms change

   24h Move

   +0.0%

   Amendment to key dates and terms for the planned rights offering.

4. Jan 23

   Proposed rights deal

   24h Move

   -5.2%

   Announcement of proposed rights offering targeting up to $12M in proceeds.

5. Jul 31

   Public equity offering

   24h Move

   -4.3%

   Closing of $8M public offering of shares and warrants under S-1.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

rights offering, subscription rights, over-subscription privilege, registration statement on Form S-1

4 terms

rights offering financial

"extended the subscription period of its previously announced rights offering until 5:00 p.m."

A rights offering is a way for a company to raise additional money by giving existing shareholders the opportunity to buy more shares at a discounted price before they are offered to the public. It’s similar to a special sale where current owners get the first chance to buy extra items at a lower cost, allowing them to increase their investment if they choose. This process matters to investors because it can affect the value of their holdings and their ability to buy new shares at favorable terms.

View in glossary

subscription rights financial

"All holders of subscription rights that wish to subscribe to the rights offering must deliver"

Subscription rights are short-term privileges given to existing shareholders to buy additional new shares before the general public, typically at a set price and in proportion to their current holdings. Think of it as getting a coupon for first dibs on extra slices of a pizza so your share of the pie doesn’t shrink; exercising them can be a cheaper way to maintain your ownership and voting power, while ignoring them can reduce your stake and potential future earnings.

over-subscription privilege financial

"pursuant to both the basic subscription right and the over-subscription privilege, to Broadridge"

An over-subscription privilege is a feature of a share offering that lets existing investors request more shares than their initial entitlement, with any extra allocation given only if other investors do not take their full allotment. It matters because it gives shareholders a chance to increase their stake and avoid losing ownership percentage, much like ordering extra slices at a party in case others pass—however, receiving the extras is not guaranteed.

registration statement on Form S-1 regulatory

"The Company’s registration statement on Form S-1 (Registration No. 333-292085) was declared effective"

A registration statement on Form S-1 is a detailed filing a company submits to the U.S. securities regulator to register new shares for public sale; it includes a plain-language prospectus, financial statements, business description and risk factors. For investors it matters because it provides the official, comprehensive blueprint of the offering — like an owner’s manual — allowing buyers to assess risks, inspect financial health and compare valuation before deciding to invest.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

OCALA, Fla., Feb. 25, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) – AIM ImmunoTech Inc. (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of its lead product, Ampligen® (rintatolimod), for the treatment of late-stage pancreatic cancer – a lethal and unmet global health problem – announced today that it has extended the subscription period of its previously announced rights offering until 5:00 p.m., Eastern Time, on Tuesday, March 3, 2026.

The subscription period for the rights offering commenced on February 11, 2026. All holders of subscription rights that wish to subscribe to the rights offering must deliver a properly completed and signed subscription rights certificate, together with payment of the full subscription price for the units the holder wishes to purchase pursuant to both the basic subscription right and the over-subscription privilege, to Broadridge Corporate Issuer Solutions, LLC (the “Subscription Agent”), to be received before 5:00 p.m., Eastern Time, on March 3, 2026. The completed rights certificate and payment should be delivered to the Subscription Agent as follows:

By UPS, FedEx or Courier:	By USPS Service:
Broadridge, Inc. Attn: BCIS IWS 51 Mercedes Way Edgewood, NY 11717	Broadridge, Inc. Attn: BCIS Re-Organization Department P.O. Box 1342 Brentwood, NY 11717-0718

The subscription rights are non-transferable and will only be exercisable during the subscription period. Once holders have exercised their subscription rights, such exercise may not be revoked, canceled, or changed, even if holders subsequently learn information about the Company or its business, financial position, results of operations or cash flows that is material or adverse or that the holders otherwise consider to be unfavorable. The Company may cancel, modify or amend the rights offering at any time and for any reason prior to the expiration of the subscription period. Subscription rights which are not exercised by the expiration date of the rights offering will expire and will have no value.

AIM has engaged Maxim Group LLC as dealer-manager for the proposed rights offering. Questions about the rights offering or requests for copies of the final prospectus may be directed to Maxim Group LLC at 300 Park Avenue, New York, NY 10022, Attention: Syndicate Department, or via email at syndicate@maximgrp.com or telephone at (212) 895-3745.

The Company’s registration statement on Form S-1 (Registration No. 333-292085) was declared effective by the Securities and Exchange Commission (“SEC”) on February 10, 2026. The prospectus relating to and describing the terms of the rights offering has been filed with the SEC as a part of the registration statement and is available on the SEC's website at http://www.sec.gov.

This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. This press release is not an offering and an offering can only be made by the prospectus and any prospectus supplements for the rights offering, which should be read carefully before making an investment decision.

The Company's stockholders as of 5:00 p.m., Eastern Time, on February 10, 2026 – the record date – should make an independent investment decision about whether to exercise their subscription rights based on their own assessment of the Company's business, financial condition, prospects for the future and the terms of the rights offering.

About AIM ImmunoTech

AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of its lead product, Ampligen® (rintatolimod), for the treatment of late-stage pancreatic cancer, a lethal and unmet global health problem. Ampligen is a dsRNA and highly selective TLR3 agonist immuno-modulator that has shown broad-spectrum activity in clinical trials.

Forward Looking Statements

Some of the statements included in this press release may be forward-looking statements that involve a number of risks and uncertainties. Among other things, for those statements, the Company claims the protection of safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements set forth in the press release speak only as of the date of the press release. The Company does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. The Company is in various stages of seeking to determine whether Ampligen® will be effective in the treatment of multiple types of viral diseases, cancers, and immune-deficiency disorders and disclosures in the Company’s reports filed with the SEC on its website and in its press releases set forth its current and anticipated future activities. These activities are subject to change for a number of reasons. Significant additional testing and trials will be required to determine whether Ampligen® will be effective in the treatment of these conditions. Results obtained in animal models do not necessarily predict results in humans. Human clinical trials will be necessary to prove whether or not Ampligen® will be efficacious in humans. No assurance can be given as to whether current or planned clinical trials will be successful or yield favorable data and the trials are subject to many factors including lack of regulatory approval(s), lack of study drug, or a change in priorities at the institutions sponsoring other trials. Even if these clinical trials are initiated, the Company cannot assure that the clinical studies will be successful or yield any useful data or require additional funding. Among the studies are clinical trials that provide only preliminary data with a small number of subjects, and no assurance can be given that the findings in these studies will prove true or that the study or studies will yield favorable results. No assurance can be given that future studies will not result in findings that are different from those reported in the studies referenced in the Company’s reports filed with the SEC, on the Company’s website and in its press releases. Operating in foreign countries carries with it a number of risks, including potential difficulties in enforcing intellectual property rights. The Company cannot assure that its potential foreign operations will not be adversely affected by these risks.

Please review the “Risk Factors” section in the Company’s latest annual report on Form 10-K and subsequent quarterly reports on Form 10-Q and the registration statement. Its filings are available at www.aimimmuno.com. The information found on the Company’s website is not incorporated by reference herein and is included for reference purposes only.

IR Contact:

JTC Team, LLC

Jenene Thomas

908.824.0775

AIM@jtcir.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When does AIM (AIM) rights offering subscription period now end?

The subscription period now ends at 5:00 p.m. ET on March 3, 2026. According to the company, holders must deliver a completed subscription rights certificate and full payment to Broadridge by that deadline to participate.

Are AIM subscription rights transferable for the March 2026 rights offering?

No, the subscription rights are non-transferable for this offering. According to the company, only the original rights holders can exercise rights during the subscription period, and unexercised rights will expire without value.

How do AIM shareholders exercise their rights in the March 2026 offering?

Shareholders must submit a properly completed and signed subscription rights certificate plus full payment to Broadridge. According to the company, delivery instructions include courier or USPS addresses and must be received by 5:00 p.m. ET on March 3, 2026.

Can AIM shareholders revoke their exercise after submitting subscription rights?

No, once exercised the subscription cannot be revoked, canceled, or changed. According to the company, exercises remain binding even if holders later learn material adverse information about the company.

Who should AIM shareholders contact with questions about the rights offering?

Contact Maxim Group LLC, the dealer-manager, via syndicate@maximgrp.com or (212) 895-3745. According to the company, Maxim Group can provide questions, prospectus copies, and guidance on subscription procedures.